Építés alatt – nem éles oldal
Belépés
Résztvevőt keresFázis nélkül

Clinical Phenotypes, Natural History, and Long-Term Outcomes of Arrhythmogenic Cardiomyopathy: The STARTER Registry

A legfontosabb adatok

Ki végzi
First Affiliated Hospital Xi'an Jiaotong University
Hol
Kína1 helyszín, 1 országbanVálassz országot a helyszínekhez
Azonosító
Állapot
Toboroz
Résztvevők
4500 fő, tervezett
Kezdés
2024. ápr. 9.
Várható befejezés
2050. dec. 31.
A vizsgálat típusa
Megfigyeléses, 2 csoport
A regiszteradat frissítve
2026. november 18.

Ki vehet részt

Nem
Nők és férfiak
Egészséges önkéntesek
Nem vehetnek részt
A regiszter összes feltétele (6)A regiszter feltételeinek elrejtése

Ki vehet részt

  • Patients of any age or sex with a clinical diagnosis of arrhythmogenic cardiomyopathy (ACM), established through comprehensive clinical evaluation based on medical and family history, electrocardiographic findings, cardiac imaging, available genetic testing results, and histopathological findings when clinically indicated. Diagnosis will refer to applicable international guidelines and consensus documents, including the 2019 Heart Rhythm Society expert consensus statement, the 2020 Padua criteria, the 2023 European Society of Cardiology guidelines for cardiomyopathies, and subsequent applicable updates
  • Availability of essential clinical information sufficient to confirm the diagnosis of ACM and establish a longitudinal clinical record, including relevant baseline and observation dates
  • Fulfillment of applicable ethical approval and informed consent requirements. For retrospective data collection, participation will be subject to approved consent waiver provisions or existing valid authorization. Prospective participants will provide informed consent through the applicable approved procedures. For minors, permission from a parent or legal guardian and age-appropriate assent will be obtained as required

Ki nem vehet részt

  • Refusal to participate, withdrawal or absence of required authorization, or failure to meet applicable ethical and informed consent requirements; Additional Considerations:; Patients with coexisting diseases, previous ventricular arrhythmias, implantable cardioverter-defibrillators, prior catheter ablation, or heart failure may be eligible if they otherwise meet the study criteria; Cardiac magnetic resonance imaging, genetic testing, and biological sample collection are not mandatory for enrollment. The absence of these investigations or samples will not be considered an exclusion criterion; Asymptomatic relatives carrying ACM-associated genetic variants who do not meet the clinical diagnostic criteria for ACM will not be included in the confirmed ACM registry cohort solely on the basis of carrier status
  • ACM diagnosis cannot be confirmed after clinical review, or the observed cardiac abnormalities and ventricular arrhythmias can be sufficiently explained by another established disease without meeting the study's diagnostic criteria for ACM
  • Insufficient essential clinical information to confirm ACM diagnosis or determine the relevant observation period, despite reasonable efforts to verify the available records

Alkalmassági kérdőív

Ez nem döntés: hogy ki vehet részt, azt csak a vizsgálat csapata mondhatja meg.

  • Arrhythmogenic cardiomyopathy

Ez a vizsgálat jelenleg itt érhető el: Kína.

Egy országban van helyszíne. Válassz országot, hogy lásd a helyszíneket.

A vizsgálatról

Mit akar kideríteni a vizsgálat

The goal of this observational study is to describe the clinical phenotypes, natural history, and long-term outcomes of arrhythmogenic cardiomyopathy (ACM) in patients of all ages.

A teljes eredeti leírásKevesebb

The main questions it aims to answer are:

* How do the clinical characteristics and disease phenotypes of patients with ACM change over time? * How often do patients with ACM experience serious ventricular arrhythmias, sudden cardiac death, heart failure, and other major clinical outcomes during long-term follow-up? * How do clinical, imaging, and genetic characteristics differ among patients with right-dominant, left-dominant, and biventricular ACM?

Researchers will observe patients with different ACM phenotypes to better understand their disease progression and long-term outcomes. No experimental treatments will be assigned.

Participants will:

* Have their existing medical records, clinical examinations, cardiac imaging, electrocardiographic findings, genetic test results (when available), and treatments reviewed. * Be followed for up to 5 years through routine clinical visits, medical records, or telephone contacts, with extended follow-up when applicable. * Optionally provide biological samples during routine clinical care, with appropriate informed consent. Providing samples is not required to participate in the study.

A vizsgálat 2 csoportja

  • Retrospective Cohort

    Patients of all ages with a clinical diagnosis of arrhythmogenic cardiomyopathy (ACM) and available medical records from January 1, 2018, through October 1, 2026, will be included retrospectively. Existing clinical data, including medical history, ventricular phenotype, electrocardiographic findings, cardiac imaging, genetic testing results when available, treatments, and documented clinical outcomes, will be collected and analyzed. Patients will be classified according to right-dominant, left-dominant, or biventricular ACM phenotypes. No research-specific interventions, additional examinations, or new biospecimen collection will be performed as part of retrospective data collection.

  • Prospective Cohort

    Patients of all ages with a clinical diagnosis of arrhythmogenic cardiomyopathy (ACM) will be prospectively enrolled and followed under routine clinical care. Clinical, electrocardiographic, imaging, genetic, treatment, and outcome data will be collected. Patients will be classified as having right-dominant, left-dominant, or biventricular ACM. Follow-up will generally occur at 6 months, 12 months, and annually during years 2 through 5 to assess serious ventricular arrhythmias, sudden cardiac death, heart failure-related events, and changes in cardiac phenotype. Optional biospecimens may be collected with appropriate consent and ethical approval. No experimental treatments or research-mandated invasive procedures will be performed.

Következő lépések

Az orvosodnak

Kérdőlap az orvosnak

PDF az orvosodnak: mit vizsgál a vizsgálat, ki vehet részt, és 1 kérdés a részvételi feltételekről, hellyel a válaszoknak és a jegyzeteknek.

A PDF letöltése

PDF, US Letter, 1–2 oldal. A4 méretben

A vizsgálati csapatnak

Kérdések a vizsgálat csapatának

  1. Milyen gyakran kell bejárnom, és egy-egy alkalom mennyi ideig tart?
  2. Megtérítik az utazási költséget?
  3. Megtarthatom a saját orvosomat?
  4. Mi történik, ha ki akarok lépni?

Contact the study team: see the registry record → Contacts and Locations

Adatok és források

Regiszteradat
Szerepel a ClinicalTrials.gov-on.
Hivatalos cím
Clinical Phenotypes, Natural History, and Long-Term Outcomes of Arrhythmogenic Cardiomyopathy: A Multicenter Retrospective and Prospective Registry Cohort Study (STARTER)
Kérdések a feltételekről
Forrás: NCT06352307: ki vehet részt
A regiszteradat frissítve
2026. november 18.